MannKind | MNKD - Interest Expense On Debt


MannKind reported $7.33M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Adma Biologics USD 1.68M 150K Sep/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Insmed USD 20.6M 217K Dec/2025
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
MacroGenics USD 3.34M 2.54M Sep/2025
MannKind USD 7.33M 1.14M Sep/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Novavax USD 4.24M 96K Sep/2024
Pfizer USD 711M 59M Dec/2025
Sanofi EUR -25M 252M Dec/2025
Xencor USD 7.66M 578K Sep/2025